Skip to main content
SK Bioscience Co.,Ltd logo

SK Bioscience Co.,Ltd — Investor Relations & Filings

Ticker · 302440 ISIN · KR7302440003 KO Manufacturing
Open in API
Filings indexed 381 across all filing types
Latest filing 2026-04-28 Transaction in Own Shar…
Country KR South Korea
Listing KO 302440

About SK Bioscience Co.,Ltd

https://www.skbioscience.com/

SK Bioscience is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines and biological products. Spun off from SK Chemicals in 2018, the company develops its own pipeline of vaccines, including cell-culture-based influenza vaccines and a COVID-19 vaccine, utilizing its established R&D and production platforms. In addition to its proprietary products, SK Bioscience provides global Contract Development and Manufacturing Organization (CDMO) services, offering end-to-end support from process development to large-scale commercial manufacturing for international partners. The company is dedicated to promoting public health by providing innovative preventative solutions to address global health challenges.

Recent filings

Filing Released Lang Actions
주요사항보고서(자기주식취득결정)
Transaction in Own Shares Classification · 1% confidence The document is a Korean ‘주요사항보고서’ (material event report) titled “자기주식 취득 결정” (Decision to acquire treasury shares) filed with the Financial Services Commission/KRX. It details the number of shares, amounts, acquisition period, methods, and relevant statutory calculations for a share repurchase. This matches “Transaction in Own Shares” (POS).
2026-04-28 Korean
기업설명회(IR)개최(안내공시)
Investor Presentation Classification · 1% confidence The document is an announcement of an upcoming investor relations conference call (“기업설명회(IR) 개최”), detailing date, time, participants, purpose, and how to access IR materials on the company website. It is not the full event transcript or a financial report, nor is it simply a regulatory notice of publication for an existing report. It is a notice for an upcoming investor presentation event. Therefore, it best fits the Investor Presentation category (IP).
2026-04-22 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a full Korean “주식등의 대량보유상황보고서” (Report on Large Shareholdings) filed under the Capital Markets Act, detailing significant changes in share ownership thresholds by major shareholders and their related parties. This corresponds exactly to a Major Shareholding Notification rather than an earnings release, management change, or other topic.
2026-03-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a Korean regulatory filing titled “임원·주요주주 특정증권등 소유상황보고서,” filed with the Securities and Futures Commission and Korea Exchange. It details an executive’s personal holdings and changes in specific securities (stock options exercised, share counts before/after, acquisition dates, etc.). This matches the definition of an insider trading/ownership report filed by company directors or executives. Therefore, it should be classified as a Director's Dealing (DIRS).
2026-03-26 Korean
최대주주등소유주식변동신고서
Director's Dealing Classification · 1% confidence The document is a “최대주주등소유주식변동신고서” (“Report of Changes in Shareholding by Major Shareholders and Insiders”) for SK바이오사이언스. It details individual executives’ share transactions (e.g., directors’ resignations and appointments with corresponding share changes). This matches an insider trading report by directors and executives, which falls under “Director’s Dealing.”
2026-03-25 Korean
[기재정정]투자판단관련주요경영사항 (21가 폐렴구균백신(GBP410)의 미국 제3상 임상시험계획 (IND) 승인)
Regulatory Filings Classification · 1% confidence The document is a Korean stock exchange filing titled ‘투자판단 관련 주요경영사항’ announcing the FDA IND approval for a Phase 3 clinical trial and related corrections. It is not an earnings release, management change, annual or interim report, nor a proxy or dividend notice. It is a routine regulatory disclosure under Korean capital markets rules, making it a general regulatory announcement. Therefore it falls under the fallback category Regulatory Filings (RNS).
2026-03-23 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.